Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4561
Source ID: NCT00672919
Associated Drug: Pioglitazone
Title: Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
Acronym: COMPLEMENT
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus
Interventions: DRUG: Pioglitazone
Outcome Measures: Primary: Change from Baseline in Triglyceride Levels, Weeks 8 and 17 or Final Visit | Secondary: Change from Baseline in Total Cholesterol, Weeks 8 and 17 or Final Visit|Change from Baseline in direct Low Density Lipoprotein cholesterol, Weeks 8 and 17 or Final Visit|Change from Baseline in High Density Lipoprotein cholesterol, Weeks 8 and 17 or Final Visit|Change from Baseline in apolipoprotein B (apoB), Weeks 8 and 17 or Final Visit|Change from Baseline in apolipoprotein A1 (apoA1), Weeks 8 and 17 or Final Visit|Change from Baseline in Free Fatty Acids, Weeks 8 and 17 or Final Visit|Change from Baseline in Lipid Fractionation, Weeks 8 and 17 or Final Visit|Change from Baseline in C-reactive Protein, Weeks 8 and 17 or Final Visit
Sponsor/Collaborators: Sponsor: Takeda
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 305
Study Type: INTERVENTIONAL
Study Designs: Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2003-11
Completion Date: 2004-08
Results First Posted:
Last Update Posted: 2012-02-28
Locations: Birmingham,, Alabama, United States|Tucson, Arizona, United States|Bellflower, California, United States|Burlingame, California, United States|Fresno,, California, United States|La Jolla, California, United States|Long Beach, California, United States|Pasadena, California, United States|Arvada, Colorado, United States|Norwalk, Connecticut, United States|Waterbury, Connecticut, United States|Aventura, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|N. Miami Beach, Florida, United States|Tallahassee, Florida, United States|West Palm Beach, Florida, United States|Columbus,, Georgia, United States|Idaho Falls, Idaho, United States|Chicago Heights, Illinois, United States|Evansville,, Indiana, United States|Des Moines, Iowa, United States|Lafayette, Louisiana, United States|Fall River, Massachusetts, United States|Waltham, Massachusetts, United States|Tupelo, Mississippi, United States|Chesterfield, Missouri, United States|Omaha, Nebraska, United States|Staten Island, New York, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Centerville, Ohio, United States|Dayton, Ohio, United States|Medford, Oregon, United States|Meadville, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Warwick, Rhode Island, United States|Chattanooga, Tennessee, United States|Morristown, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Orange, Virginia, United States|Virginia Beach,, Virginia, United States|Man, West Virginia, United States|Wausau, Wisconsin, United States|Carolina, Puerto Rico|PoncE, Puerto Rico
URL: https://clinicaltrials.gov/show/NCT00672919

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D336 Pioglitazone small molecule DB01132 Details